Login to Your Account



Avastin's Survival Data In NSCLC Sends Genentech Soaring, Again

By Karen Pihl-Carey


Wednesday, March 16, 2005
Genentech Inc.'s stock climbed 25 percent in late-day trading Monday after news that a Phase III trial of Avastin met its primary endpoint of survival in non-small-cell lung cancer patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription